Research & Development
ERX Pharmaceuticals is focused on the discovery and development of innovative drugs for the treatment of obesity and related diseases. ERX-1000, ERX’s lead drug candidate, is a first-in-class leptin sensitizer in Phase 1 clinical trials for the treatment of obesity. The research and development pipeline also includes preclinical and discovery stage candidates, including ERX-2000 for diabetes.
![](https://www.erxpharmaceuticals.com/wp-content/uploads/2019/06/female-scientist-uses-tablet-computer-in-the-modern-brain-study-and-picture-id925425714.jpg)
Targeting Leptin Resistance
ERX is developing first-in-class leptin sensitizers as a therapeutic approach to overcome the state of leptin resistance in obesity and related diseases.
![](https://www.erxpharmaceuticals.com/wp-content/uploads/2019/06/iStock-155381213-removebg-medium-1024x648.png)
![](https://www.erxpharmaceuticals.com/wp-content/uploads/2019/07/female-chemist-analyzing-something-through-a-microscope-in-laboratory-picture-id504615018-1.jpg)
Future Development Candidates
ERX’s product pipeline includes the lead clinical candidate ERX-1000, as well as other leptin sensitizers that exhibit differentiated properties.
Learn More About ERX’s Research Efforts
![](https://www.erxpharmaceuticals.com/wp-content/uploads/2019/06/doctor-fees-picture-id537417114.jpg)
Articles and Publications
A great deal of research into leptin and leptin sensitization has been completed since the discovery of the leptin hormone in 1994. Previous research pointing to leptin resistance as a driver of obesity has helped inform our approach.